Intellia Therapeutics, Inc. (NTLA) insider trading

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

John M Leonard

President and CEO

—

$107.91K (1) scheduled

−$107.91K

1,196,479

0.8539%

$14.35M

+17.5%

Fred E Cohen

Director

—

216,653

0.1546%

$2.60M

+338.1%

Jing L. Marantz

EVP, Chief Medical Officer

—

199,822

0.1426%

$2.40M

—

James Basta

EVP, General Counsel

—

156,794

0.1119%

$1.88M

+70.5%

Edward J Dulac III

EVP, Chief Financial Officer

—

148,175

0.1057%

$1.78M

+123.4%

William J Chase

Director

—

143,893

0.1027%

$1.73M

+439.1%

Birgit C Schultes

EVP, Chief Scientific Officer

—

137,733

0.0983%

$1.65M

+98.3%

David Lebwohl

EVP, Chief Medical Officer

—

131,192

0.0936%

$1.57M

+36.2%

Eliana Clark

EVP, Chief Technical Officer

—

93,864

0.0670%

$1.13M

+26.3%

Laura Sepp-Lorenzino

EVP, Chief Scientific Officer

—

77,388

0.0552%

$927.88K

−6.6%

Michael P Dube

VP, Chief Accounting Officer

—

65,022

0.0464%

$779.61K

+38.3%

Derek Hicks

EVP, Chief Business Officer

—

59,878

0.0427%

$717.94K

−9.8%

Georgia Keresty

Director

—

41,083

0.0293%

$492.59K

+72.0%

Muna Bhanji

Director

—

36,403

0.0260%

$436.47K

+84.5%

Frank Verwiel

Director

—

35,148

0.0251%

$421.42K

+95.8%

Jesse Goodman

Director

—

33,559

0.0239%

$402.37K

+72.5%

Brian Goff

Director

—

32,609

0.0233%

$390.98K

+111.6%

Intellia Therapeutics, Inc.

What the insiders did Scheduled selling only

By person